-
1 Comment
Ono Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 16.4% below its 200 day moving average.
From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.7.
Ono Pharmaceutical Co., Ltd's total revenue rose by 10.7% to $84B since the same quarter in the previous year.
Its net income has increased by 40.1% to $27B since the same quarter in the previous year.
Finally, its free cash flow grew by 50.9% to $16B since the same quarter in the previous year.
Based on the above factors, Ono Pharmaceutical Co., Ltd gets an overall score of 4/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - General |
| ISIN | JP3197600004 |
| Exchange | TSE |
| CurrencyCode | JPY |
| Market Cap | 769B |
|---|---|
| PE Ratio | 10.37 |
| Target Price | 1708.3334 |
| Dividend Yield | 4.8% |
| Beta | 0.17 |
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4528.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
